Pro‐protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 7, 2015-07 ,pp. : 738-742

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 36, Iss. 1, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Myopathy in older people receiving statin therapy: a systematic review and meta‐analysis

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 3, 2015-09 ,pp. : 363-371

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmaceutical interventions in antiretroviral therapy: systematic review and meta‐analysis of randomized clinical trials

By  

JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol. 40, Iss. 3, 2015-06 ,pp. : 251-258

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 36, Iss. 1, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite